Targeted Therapies in HER2-Positive Breast Cancer – a Systematic Review

Amelie Schramm  Nikolaus De Gregorio  Peter Widschwendter  Visnja Fink  Jens Huober
Department of Gynecology and Obstetrics, University Hospital Ulm, Germany

Keywords
HER2-positive breast cancer · Targeted therapies · Dual HER2 blockade

Summary
About 20% of all breast cancer patients have a human epidermal growth factor receptor 2 (HER2)-positive breast tumor. This entity underwent an impressive change in prognosis, with notable improvement of progression-free survival and overall survival. Due to more aggressive tumors and no specific therapy, HER2 overexpression was historically seen as a negative prognostic marker, with worse prognosis and increased risk of recurrent disease. Trastuzumab, the first anti-HER2 antibody, revolutionized the systemic therapy options in HER2-positive breast cancer and initiated several targeted therapies and more personalized treatment strategies. Over the years, multiple HER2-targeting drugs stepped into clinical practice, for the curative as well as the metastatic situation. This review summarizes the targeted treatment options in HER2-positive breast cancer and their current impact in the clinical routine. Results of the most outstanding trials in HER2-targeted therapies and important ongoing trials are subsequently described for an up-to-date overview.

Introduction
Worldwide, breast cancer is the most frequent cancer in women and, thus, disease management is well investigated. Nevertheless, due to various histological subtypes with mainly ductal and lobular adenocarcinomas and differences in receptor expression and genetic profiles, multiple therapy options exist. The majority of the adenocarcinomas are hormone receptor (HR) positive and approximately 20% of the malignant breast tumors show an overexpression of human epidermal growth factor receptor 2 (HER2) on their cell surface [1]. Identification of receptor expression offers treatment options for individualized targeted therapies.

Human Epidermal Growth Factor Receptor 2
HER2 is part of the ErbB family, which consists of 4 plasma membrane-bound receptor tyrosine kinases with HER1 (human epithelial growth factor receptor ErbB1), HER2 (Neu, ErbB2), HER3 (ErbB3), and HER4 (ErbB4). Signaling occurs through ligand-dependent activation by external ligands like epidermal growth factor (EGF) and transforming growth factor α (TGFα) or ligand-independent activation by receptor dimerization through interaction with other HER family members (homo-/heterodimeri- zation). Specifically, in HER2, activation of signal transduction can also occur by proteolytic cleavage of the extracellular domain. Like other ErbB receptors, the HER2 receptor has an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain which mediates cell proliferation and apoptosis. Through intrinsic intracellular protein tyrosine kinase activity, receptor dimerization causes autophosphorylation within the cytoplasmic domain and thereby downstream signaling via pathways like the mitogen-activated protein kinase (MAP kinase) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways [2–5]. Overexpression of the proto-oncogene HER2 plays an important role in breast cancer and is also found in several other cancer types like stomach and ovarian cancer or endometrial carcinoma. Besides HER2 overexpression, other gene amplifications and alterations with spontaneous receptor dimerization in the absence of a ligand and receptor activation, with subsequent cell proliferation, have been described as well.
**HER2 Definition**

Overexpression of HER2 in breast cancer is analyzed by immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH) on histopathological samples of primary cancer or metastatic tissue.

According to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP), HER2 positivity is defined by an IHC score of 3+, with strong staining of more than 10% of all invasive tumor cells. An IHC score of 2+ needs further investigation whereas IHC scores of 0 and 1+ are representative of HER2 negativity.

For an additional determination after an IHC score of 2+ and also as a standalone test, a FISH analysis can be performed. FISH is based on the HER2 gene copy number and the number of chromosome 17 centromeres (CEP17). The ASCO and CAP define the presence of a HER2 amplification in FISH analysis as a dual-probe HER2/CEP17 ratio of $\geq 2.0$ or a single-probe average HER2 copy number of $\geq 6.0$ signals/cell [6].

**HER2-Targeted Drugs**

**Lapatinib**

Lapatinib is a dual tyrosine kinase inhibitor that binds to the intracellular ATP-binding pocket of the protein kinase domain of HER2. By binding, lapatinib prevents autophosphorylation of the cytoplasmic domain and thereby downstream signaling and tumor cell growth [7–9].

**Trastuzumab**

Trastuzumab is a monoclonal antibody that binds to the extracellular subdomain IV of HER2. Various, partly not well understood, mechanisms lead to the inhibition of tumor cell proliferation and tumor angiogenesis. Besides the blockade of ligand-independent HER2 signaling with the prevention of homodimerization and signal transduction, trastuzumab is thought to cause apoptosis by antibody-dependent cell-mediated cytotoxicity (ADCC). As another effect, trastuzumab also prevents the proteolytic cleavage of the extracellular domain [10–12].

**Pertuzumab**

Pertuzumab is a recombinant, humanized monoclonal antibody that acts as a HER2 dimerization inhibitor by binding to the extracellular dimerization domain. Heterodimerization with other HER2 family members like HER3 is blocked. This prevents ligand-initiated intracellular signaling through 2 major signaling pathways, the MAP kinase and PI3K pathways, and thereby cell cycle arrest of cells with HER2 overexpression. Also ADCC seems to be induced by pertuzumab. The combination of trastuzumab and pertuzumab acts synergistically, with complementary inhibition of HER2 signaling by blocking ligand-dependent- and -independent signaling as well as homo- and heterodimerization [13–16].

**Trastuzumab emtansine**

Trastuzumab emtansine (T-DM1) is the newest treatment option in HER2-positive breast cancer and unifies the idea of chemotherapy (CHT) and targeted therapies. In this drug, the cytotoxic and antimitotic maytansine derivative DM1 is linked to trastuzumab. Thereby, the CHT agent only acts in cells that present the targeted antigen on their cell surface, and systemic toxicity is limited. A current hypothesis suggests that the antitumor activity works through receptor-mediated internalization and intracellular release of DM1. By inhibition of microtubules, DM1 mediates its antiproliferative effects [17, 18].

**Combination of HER2-Targeted Therapies**

Up to 70% of all patients treated with trastuzumab-based therapy in the metastatic setting develop resistance against their prior HER2-targeted therapy [19–21]. To overcome this resistance, combined HER2-targeted therapies are tested in different variations. The combination of trastuzumab and pertuzumab effectively blocks tumor cell proliferation ex vivo and in vivo [13, 22]. In the metastatic setting, dual antibody blockade has already been approved and is used in the clinical routine. Recent data show promising results also for the neoadjuvant setting (see ‘Anti-HER2 in the Neoadjuvant Setting’). Also a combination of trastuzumab and lapatinib improves the clinical benefit rate (CBR) and progression-free survival (PFS) compared to lapatinib alone, in patients with metastatic breast cancer (MBC) progressing on prior trastuzumab treatment.

**HER2-Targeted Therapy in Clinical Trials**

**Adjuvant HER2 Treatment**

There were 4 important studies, first presented at the ASCO Annual Meeting 2005, which initiated trastuzumab use in adjuvant treatment (fig. 1). The Herceptin Adjuvant Trial (HERA – NCT00045032) enrolled 5,090 women with HER2-positive early breast cancer after completion of locoregional therapy (surgery ± radiotherapy) and at least 4 courses of CHT. Patients were randomized to either a control group or 1 or 2 years of treatment with...
Trastuzumab. A first analysis (after 1 year (median) of follow-up) indicated the benefit of trastuzumab in adjuvant systemic therapy with an unadjusted hazard ratio (HR) of 0.54 for an event in the trastuzumab group (1 year) compared to the observation group [23]. A final comparison of the interventional arms showed no evidence of better outcome with 2 years versus 1 year of trastuzumab. Nevertheless, the number of adverse cardiac events slightly rises through 2 years of drug administration compared to 2 years. The HR for disease-free survival (DFS) and also for overall survival (OS) was 0.76 each, for 1 year of trastuzumab treatment versus observation, which confirms the efficacy of trastuzumab therapy [24].

The results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial and the North Central Cancer Treatment Group (NCCTG) N9831 trial were presented in 1 analysis. In both trials, 4,046 women with HER2-positive early-stage breast cancer were treated with CHT comprising 4 cycles of doxorubicin and cyclophosphamide (AC) followed by paclitaxel for 3 months (weekly or q21d). The NSABP B-31 study randomized patients to CHT with or without 52 weeks of trastuzumab administration afterwards. The NCCTG N9831 study had 3 arms with only CHT, CHT plus trastuzumab simultaneously (with paclitaxel) or plus trastuzumab sequentially (after paclitaxel). The interim and final analyses of the trials did demonstrate the benefit of addition of trastuzumab for DFS and OS, by increasing the 10-year OS rate from 75.2% to 84%, thus leading to a 37% relative improvement in OS (HR 0.63, P < 0.001). Also, the DFS benefits from trastuzumab, with an increase of the 10-year DFS rate from 62.2% to 73.7%. Thus, HER2 blockade results in a 40% (HR 0.60, P < 0.001) improvement of the DFS [25, 26]. Further analysis in the NCCTG N9831 study was done regarding the efficacy of concurrent versus sequential administration of trastuzumab. Although the analysis results were not statistically significant, they showed a trend of a prolonged DFS in the concurrent treatment arm (concurrent/sequential HR 0.77; 99.9% confidence interval (CI), 0.53–1.10, P = 0.02) and supported the recommendation of a concurrent regimen with taxane CHT [27].

Another adjuvant trial was the Breast Cancer International Research Group (BCIRG)-006 study (NCT00021255), which investigated the efficacy of trastuzumab as well as the effectiveness and safety of an anthracycline-free CHT regimen in order to reduce cardiac toxicity. After randomization, 3,222 women with HER2-positive early-stage high-risk breast cancer were treated with doxorubicin, cyclophosphamide, and docetaxel (ACT). ACT plus trastuzumab for 1 year (AC-TH), or with the non-anthracycline regimen consisting of docetaxel, carboplatin, and 52 weeks of trastuzumab (TCH). The final analysis underlined the importance of trastuzumab treatment, with superiority of both the trastuzumab-containing regimens compared to ACT (OS 87%, DFS 75%). Even though no significant difference in OS and DFS was seen for AC-TH (OS 92%, DFS 84%) and TCH (OS 91%, DFS 81%), there was a trend for better outcome in the AC-TH arm compared to TCH (124 vs. 144 distant relapse events). Cardiotoxicity was lower in the TCH arm. Especially for patients with high risk of congestive heart failure, the TCH regimen is thus an appropriate alternative [28].

The NCCTG N9831 study was done regarding the efficacy of concurrent versus sequential administration of trastuzumab. Although the analysis results were not statistically significant, they showed a trend of a prolonged DFS in the concurrent treatment arm (concurrent/sequential HR 0.77; 99.9% confidence interval (CI), 0.53–1.10, P = 0.02) and supported the recommendation of a concurrent regimen with taxane CHT [27].

Another adjuvant trial was the Breast Cancer International Research Group (BCIRG)-006 study (NCT00021255), which investigated the efficacy of trastuzumab as well as the effectiveness and safety of an anthracycline-free CHT regimen in order to reduce cardiac toxicity. After randomization, 3,222 women with HER2-positive early-stage high-risk breast cancer were treated with doxorubicin, cyclophosphamide, and docetaxel (ACT). ACT plus trastuzumab for 1 year (AC-TH), or with the non-anthracycline regimen consisting of docetaxel, carboplatin, and 52 weeks of trastuzumab (TCH). The final analysis underlined the importance of trastuzumab treatment, with superiority of both the trastuzumab-containing regimens compared to ACT (OS 87%, DFS 75%). Even though no significant difference in OS and DFS was seen for AC-TH (OS 92%, DFS 84%) and TCH (OS 91%, DFS 81%), there was a trend for better outcome in the AC-TH arm compared to TCH (124 vs. 144 distant relapse events). Cardiotoxicity was lower in the TCH arm. Especially for patients with high risk of congestive heart failure, the TCH regimen is thus an appropriate alternative [28].

The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO – NCT00491039) trial was initiated to analyze the efficacy of combination therapy in adjuvant treatment. With more than 8,000 participants, the trial was the largest study on adjuvant therapy in HER2-positive breast cancer. Women were treated with surgery and CHT (anthracycline based vs. anthracycline free), followed by randomization to trastuzumab alone, lapatinib alone, trastuzumab followed by lapatinib, or concurrent therapy with lapatinib and trastuzumab. Anti-HER2 therapy was given for 52 weeks and was combined with paclitaxel/docetaxel in women with prior anthracycline-based CHT for the first 12 weeks. The lapatinib arm was prematurely closed since an interim analysis in 2011 suggested inferiority of this arm. First results were presented at the ASCO Annual Meeting 2014. After 4 years of follow-up, the DFS rate for trastuzumab plus lapatinib amounts to 88% compared to 86% for trastuzumab monotherapy (HR 0.84, 97.5% CI 0.7–1.02, P = 0.048) and 87% for trastuzumab followed by lapatinib versus 86% for trastuzumab monotherapy (HR 0.96, 97.5% CI 0.8–1.25, P = 0.610). In addition the combination of trastuzumab and lapatinib showed no benefit regarding OS compared to trastuzumab. Adverse events were more likely in patients within the lapatinib arm; the overall cardiac toxicity was tolerable [29].

For an evaluation of single standard treatment in patients with small, node-negative HER2-positive breast cancer, Tolaney et al. [30] recruited 406 patients in a single-group study. Women were treated with paclitaxel and trastuzumab for 12 weeks, followed by trastuzumab monotherapy for 40 weeks. The 3-year rate of survival free from invasive disease was 98.7% (95% CI 97.6–99.8) and the 3-year rate of recurrence-free survival was 99.2% (95% CI 98.4–1.25, P = 0.610). With a risk of early recurrence of about 2% and a low rate of serious toxic effects (symptomatic congestive heart failure 0.5%), treatment with adjuvant paclitaxel and trastuzumab could be considered as an option for node-negative, small HER2-positive breast cancer.

Anti-HER2 in the Neoadjuvant Setting
Neoadjuvant CHT offers an in vivo assessment of tumor response. One of the first trials (fig. 2) underlining the concept of dual blockade was the phase III GeparQuinto trial (NCT00567554), in which the addition of trastuzumab versus lapatinib to anthracycline-taxane-based neoadjuvant CHT was tested. 620 women with operable or locally advanced HER2-positive breast cancer were
treated either with epirubicin, cyclophosphamide and docetaxel plus trastuzumab or the same CHT plus lapatinib for a total of 6 months and underwent surgery afterwards. The trastuzumab arm showed a significantly better pathological complete response (pCR) rate, with 30.3% versus 22.7% in the lapatinib group. Thus, the authors oppose the routine use of lapatinib as a single targeted agent in combination with neoadjuvant CHT [31].

In the NeoALTTO trial (NCT00553358), the combination of lapatinib and trastuzumab with neoadjuvant CHT was evaluated systematically. Women with operable HER2-positive breast cancer were assigned to treatment with paclitaxel and lapatinib only, trastuzumab only, or a combination of lapatinib and trastuzumab for 3 months. For all patients, paclitaxel CHT started only after 6 weeks of HER2 blockade. Subsequent to surgery, a systemic therapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) as well as completion of anti-HER2 therapy were performed (overall 52 weeks of lapatinib, trastuzumab, or lapatinib plus trastuzumab). No significant differences in the pCR rates were found for trastuzumab alone (29.5%) and lapatinib alone (24.7%) whereas the combination therapy of trastuzumab and lapatinib resulted in pCR rates of 51.3%. Interestingly, women with HR-negative tumors had better pCR rates after combination therapy than patients with HR-positive tumors (61.33% vs. 41.56%; 95% CI). Differences were also seen in the lapatinib cohort (pCR rates: HR negative 33.78% vs. HR positive 16.25%; 95% CI) and the trastuzumab group (36.49% vs. 22.67%; 95% CI) [32].

Within the open-label phase II trial ‘Neoadjuvant Study of Pertuzumab and Herceptin in an Early Regimen Evaluation’ (NeoSphere – NCT00545688), 417 patients with locally advanced, inflammatory or early-stage invasive HER2-positive breast cancer were randomized into 4 therapy arms. Cohort A was treated with trastuzumab plus docetaxel, cohort B with pertuzumab, trastuzumab, and docetaxel, group C received pertuzumab and trastuzumab, and group D received pertuzumab plus docetaxel for 4 neoadjuvant cycles. CHT was followed by surgery and adjuvant systemic therapy (further CHT and 52 weeks of trastuzumab). pCR and safety were evaluated, with significantly improved pCR rates found in group B with pertuzumab and trastuzumab plus docetaxel (45.8%) compared to only docetaxel plus trastuzumab (group A; 29.0%). Interestingly, group C had pCR rates of 16.8% with only dual HER2-targeted therapy; group D (pertuzumab plus docetaxel) had pCR rates of 24.0%. Also in the NeoSphere trial, women with HR-negative tumors had better pCR rates than women with HR-positive tumors. The pCR rates for group A were 20.0% (HR positive) versus 36.8% (HR negative), for group B 26.0% versus 63.2%, for group C 5.9% versus 27.3%, and in group D 17.4% versus 30.0%. Combination of trastuzumab and pertuzumab was not shown to increase cardiac toxicity [33].

HER2 Blockade in MBC
Several large trials have been conducted comparing single-agent CHT with or without trastuzumab (fig 3), one of the first being the study by Slamon et al. [34], which started recruiting in 1995. 469 women were randomized to standard CHT with or without additional trastuzumab (H) administration. Anthracycline (A; either doxorubicin or epirubicin) plus cyclophosphamide (C) or paclitaxel (P) were given for at least 6 courses; trastuzumab application did continue until disease progression. The results showed significantly increased clinical benefit for the combination of trastuzumab with first-line CHT. With trastuzumab, the time to disease progression was extended from 4.6 to 7.4 months (median) (P < 0.001), the rate of objective response (OR) was 50% compared to 32% (P < 0.001), and the median survival was prolonged to 25.1 compared to 20.3 months (P = 0.01), even though the majority of patients without trastuzumab crossed over to trastuzumab in the second line. The risk of death was reduced by 20% with addition of trastuzumab. However, the risk for cardiac toxicity with cardiac dysfunction of New York Heart Association class III or IV was clearly higher in the trastuzumab groups, especially for women treated with trastuzumab and anthracycline-based CHT regimens (27% in the AC + H group; 8% in the group with AC alone; 13% in the P + H group; and only 1% for P alone).

Several years later, the placebo-controlled CLEOPATRA trial (NCT00567190) analyzed the benefit of the addition of pertuzumab to therapy with docetaxel and trastuzumab in women with HER2-positive first-line MBC. With an improvement of 6.3 months (12.4 vs. 18.7 months), the PFS was significantly longer with pertuzumab/trastuzumab (HR 0.68, 95% CI 0.58–0.80). Also the median OS was 15.7 months longer for patients randomized to the dual HER2-targeted therapy arm, with 56.5 versus 40.8 months for placebo plus trastuzumab [35].

The efficacy of TDM-1 in MBC was already proven by a couple of trials, e.g. the Emilia trial (NCT00829166), in which 991 women with HER2-positive advanced breast cancer and previous treatment with trastuzumab plus taxane were randomly assigned to 2 treatment arms, one arm receiving T-DM1 and the other arm receiving lapatinib plus capcitabine. Whereas the PFS and median OS were significantly better for the T-DM1 arm (PFS: 9.6 vs. 6.4 months, HR 0.65, 95% CI 0.55–0.77, P < 0.001; OS: 30.9 months vs. 25.1 months, HR 0.68, 95% CI 0.55–0.85, P < 0.001), the rate of toxicities was higher in the lapatinib/capcitabine cohort. About 57% of all patients suffered from adverse events grade 3 or 4 compared to only 41% in the TDM-1 group. According to these results, T-DM1 seems to be a great option in second-line therapy and is
Systemic treatment recommendations in HER2-positive breast cancer are highly influenced by clinical research and results from the described trials. The German Working Group for Gynecological Oncology (AGO) recommends anti-HER2 treatment with trastuzumab for 1 year in addition to CHT as standard therapy for early HER2-positive breast cancer. Trastuzumab is recommended to be given concurrently to taxanes. For HER2-positive metastatic disease, CHT with docetaxel plus trastuzumab and pertuzumab is preferred. For progressive disease, TDM-1 and later combination of lapatinib and capecitabine are recommended [37, 38].

Conclusions

Targeted therapies offer selective treatment options; in case of HER2-positive breast cancer, they emerged as real game changers with most often very little additional toxicity. Especially in HER2-positive breast cancer, targeted therapies are well established and have been proven as irreplaceable part of anticancer strategies. New substances and combinations are expected to enter the clinical routine in the near future. HER2-targeted therapies are excellent examples of the effective advancement of molecular findings to clinical use by translational research and by using individual characteristics of malignant tumors.

Disclosure Statement

J.H. is a member of the Roche, GSK, and Novartis advisory boards. All other authors do not have any conflicts of interest.

References

2. Graus-Porta D, Beeli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647–1655.


